Nintedanib and Idiopathic Pulmonary Fibrosis

This chapter explores the implications of a clinical trial on Nintedanib for treating idiopathic pulmonary fibrosis, emphasizing post-marketing data and mortality benefits. The discussion highlights the need for personalized treatment approaches, differences between antifibrotic medications, and the potential for future advancements in care strategies.